A metabolic phenotype based on mitochondrial ribosomal protein expression as a predictor of lymph node metastasis in papillary thyroid carcinoma

Medicine (United States)

Volumn 94, Issue 2, 2015, Pages e380-

  Lee, Jandee ^a   Seol, Mi Youn ^a   Jeong, Seonhyang ^a   Lee, Cho Rok ^a   Ku, Cheol Ryong ^a   Kang, Sang Wook ^a   Jeong, Jong Ju ^a   Shin, Dong Yeob ^a   Nam, Kee Hyun ^a   Lee, Eun Jig ^a   Chung, Woong Youn ^a   Jo, Young Suk ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; MESSENGER RNA; MITOCHONDRIAL DNA; MITOCHONDRIAL PROTEIN; MITOCHONDRIAL RIBOSOMAL PROTEIN; RIBOSOME PROTEIN; UNCLASSIFIED DRUG; MITOCHONDRIAL RIBOSOMAL PROTEIN L44, HUMAN; TUMOR MARKER;

ACIDIFICATION; ADULT; ARTICLE; CANCER PROGNOSIS; CANCER TISSUE; CORRELATIONAL STUDY; CROSS-SECTIONAL STUDY; FEMALE; GENE EXPRESSION; GENE REGULATORY NETWORK; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; THYROID CARCINOMA; CARCINOMA; CELL TRANSFORMATION; CONFIDENCE INTERVAL; GENE EXPRESSION PROFILING; GENETICS; LYMPH NODE; LYMPHATIC METASTASIS; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; NECK; NUCLEAR REPROGRAMMING; PATHOLOGY; PROGNOSIS; SOUTH KOREA; THYROID TUMOR;

CARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; CELLULAR REPROGRAMMING; CONFIDENCE INTERVALS; CROSS-SECTIONAL STUDIES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MITOCHONDRIAL PROTEINS; MULTIVARIATE ANALYSIS; NECK; OXIDATIVE PHOSPHORYLATION; PROGNOSIS; REPUBLIC OF KOREA; RIBOSOMAL PROTEINS; RNA, MESSENGER; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84921981382     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000000380     Document Type: Article

References (32)

1. Jung CK, Little MP, Lubin JH, et al. The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab. 2014;99:E276-E285.
2. American Thyroid Association Guidelines Taskforce on Thyroid N. Differentiated Thyroid CCooper DS, et al. . Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-1214.
3. Noguchi S, Yamashita H, Uchino S, et al. Papillary microcarcinoma. World J Surg. 2008;32:747-753.
4. Mazzaferri EL, Sipos J. Should all patients with subcentimeter thyroid nodules undergo fine-needle aspiration biopsy and preoperative neck ultrasonography to define the extent of tumor invasion? Thyroid. 2008;18:597-602.
5. Bilimoria KY, Bentrem DJ, Ko CY, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg. 2007;246:375-381.
6. Cho BY, Choi HS, Park YJ, et al. Changes in the clinicopathological characteristics and outcomes of thyroid cancer in Korea over the past four decades. Thyroid. 2013;23:797-804.
7. Hsiao SJ, Nikiforov Y. Molecular approaches to thyroid cancer diagnosis. Endocr Relat Cancer. 2014;21:T30-T313.
8. Orlandi F, Saggiorato E, Pivano G, et al. Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res. 1998;58:3015-3020.
9. Liu YY, Morreau H, Kievit J, et al. Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma. Eur J Endocrinol. 2008;158:375-384.
10. Miettinen M, Karkkainen P. Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours. Preferential reactivity with malignant tumours. Virchows Arch. 1996;429:213-219.
11. Warburg O. On the origin of cancer cells. Science. 1956;123:309-314.
12. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4:891-899.
13. Kim JW, Dang CV. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res. 2006;66:8927-8930.
14. Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci. 2010;35:427-433.
15. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765-773.
16. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361:1058-1066.
17. Galluzzi L, Kepp O, Vander Heiden MG, et al. Metabolic targets for cancer therapy. Nat Rev Drug Discov. 2013;12:829-846.
18. Pavlides S, Whitaker-Menezes D, Castello-Cros R, et al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle. 2009;8:3984-4001.
19. Unwin RD, Craven RA, Harnden P, et al. Proteomic changes in renal cancer and co-ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect. Proteomics. 2003;3:1620-1632.
20. Pollak M. Targeting oxidative phosphorylation: why, when, and how. Cancer Cell. 2013;23:263-264.
21. Schweppe RE, Klopper JP, Korch C, et al. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab. 2008;93:4331-4341.
22. Mouchiroud L, Houtkooper RH, Moullan N, et al. The NAD(\+)/sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling. Cell. 2013;154:430-441.
23. Houtkooper RH, Mouchiroud L, Ryu D, et al. Mitonuclear protein imbalance as a conserved longevity mechanism. Nature. 2013;497:451-457.
24. Kim SJ, Kwon MC, Ryu MJ, et al. CRIF1 is essential for the synthesis and insertion of oxidative phosphorylation polypeptides in the mammalian mitochondrial membrane. Cell Metab. 2012;16:274-283.
25. Bustamante E, Pedersen PL. High aerobic glycolysis of rat hepatoma cells in culture: role of mitochondrial hexokinase. Proc Natl Acad Sci USA. 1977;74:3735-3739.
26. Christofk HR, Vander Heiden MG, Harris MH, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008;452:230-233.
27. Acin-Perez R, Fernandez-Silva P, Peleato ML, et al. Respiratory active mitochondrial supercomplexes. Mol Cell. 2008;32:529-539.
28. Bauerschmitt H, Funes S, Herrmann JM. Synthesis and sorting of mitochondrial translation products. Methods Mol Biol. 2008;457:95-112.
29. Dudkina NV, Eubel H, Keegstra W, et al. Structure of a mitochondrial supercomplex formed by respiratory-chain complexes I and III. Proc Natl Acad Sci USA. 2005;102:3225-3229.
30. Kramer G, Boehringer D, Ban N, et al. The ribosome as a platform for co-translational processing, folding and targeting of newly synthesized proteins. Nat Struct Mol Biol. 2009;16:589-597.
31. Galper JB. Mitochondrial protein synthesis in HeLa cells. J Cell Biol. 1974;60:755-763.
32. Savagner F, Chevrollier A, Loiseau D, et al. Mitochondrial activity in XTC.UC1 cells derived from thyroid oncocytoma. Thyroid. 2001;11:327-333.